Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JV001 in Heart Failure Due to Dilated Cardiomyopathy
NCT05837143Phase 1Active, not recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Mar 2023
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JV-001 in dilated cardiomyopathy (DCM), sponsored by Shanghai East Hospital. Primary endpoints: Dose-limiting toxicity at 28 days and Incidence of adverse events and serious adverse events at 1 year. Started Mar 2023; status: active, not recruiting.
02
Drugs
JV-001
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT05837143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05837143.